The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Vaccination


Psychiatry related information on Vaccination


High impact information on Vaccination


Chemical compound and disease context of Vaccination


Biological context of Vaccination


Anatomical context of Vaccination


Associations of Vaccination with chemical compounds


Gene context of Vaccination

  • These data indicate that TLR1 and TLR2 are required for lipoprotein recognition and that defects in the TLR1/2 signaling pathway may account for human hyporesponsiveness to OspA vaccination [34].
  • Mice deficient for the major MCP-1 receptor, CC chemokine receptor (CCR)2, did not develop EAE after active immunization but generated effector cells that could transfer the disease to naive wild-type recipients [27].
  • These results indicate that Cot/Tpl2 is an important negative regulator of Th1-type adaptive immunity, that it achieves this regulation by inhibiting IL-12 production from accessory cells, and that it might be a potential target molecule in CpG-DNA-guided vaccination [35].
  • Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist [36].
  • Vaccination with B16 cells producing IL-4 or gamma-interferon had no effect, and vaccination with B16 cells producing IL-2 decreased survival time [37].

Analytical, diagnostic and therapeutic context of Vaccination


  1. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. Redfield, R.R., Birx, D.L., Ketter, N., Tramont, E., Polonis, V., Davis, C., Brundage, J.F., Smith, G., Johnson, S., Fowler, A. N. Engl. J. Med. (1991) [Pubmed]
  2. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. Barlow, W.E., Davis, R.L., Glasser, J.W., Rhodes, P.H., Thompson, R.S., Mullooly, J.P., Black, S.B., Shinefield, H.R., Ward, J.I., Marcy, S.M., DeStefano, F., Chen, R.T., Immanuel, V., Pearson, J.A., Vadheim, C.M., Rebolledo, V., Christakis, D., Benson, P.J., Lewis, N. N. Engl. J. Med. (2001) [Pubmed]
  3. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. McShane, H., Pathan, A.A., Sander, C.R., Keating, S.M., Gilbert, S.C., Huygen, K., Fletcher, H.A., Hill, A.V. Nat. Med. (2004) [Pubmed]
  4. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Wynn, T.A., Cheever, A.W., Jankovic, D., Poindexter, R.W., Caspar, P., Lewis, F.A., Sher, A. Nature (1995) [Pubmed]
  5. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Gallimore, A., Cranage, M., Cook, N., Almond, N., Bootman, J., Rud, E., Silvera, P., Dennis, M., Corcoran, T., Stott, J. Nat. Med. (1995) [Pubmed]
  6. Suppression of psychoactive effects of cocaine by active immunization. Carrera, M.R., Ashley, J.A., Parsons, L.H., Wirsching, P., Koob, G.F., Janda, K.D. Nature (1995) [Pubmed]
  7. Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration. Frenkel, D., Katz, O., Solomon, B. Proc. Natl. Acad. Sci. U.S.A. (2000) [Pubmed]
  8. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Rasmussen, T., Hansson, L., Osterborg, A., Johnsen, H.E., Mellstedt, H. Blood (2003) [Pubmed]
  9. Anti-Abeta: The good, the bad, and the unforeseen. Broytman, O., Malter, J.S. J. Neurosci. Res. (2004) [Pubmed]
  10. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. LeSage, M.G., Keyler, D.E., Hieda, Y., Collins, G., Burroughs, D., Le, C., Pentel, P.R. Psychopharmacology (Berl.) (2006) [Pubmed]
  11. Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination. Densen, P., Weiler, J.M., Griffiss, J.M., Hoffmann, L.G. N. Engl. J. Med. (1987) [Pubmed]
  12. Depression of aminopyrine metabolism by influenza vaccination. Kramer, P., McClain, C.J. N. Engl. J. Med. (1981) [Pubmed]
  13. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Klyubin, I., Walsh, D.M., Lemere, C.A., Cullen, W.K., Shankar, G.M., Betts, V., Spooner, E.T., Jiang, L., Anwyl, R., Selkoe, D.J., Rowan, M.J. Nat. Med. (2005) [Pubmed]
  14. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Reeves, P.M., Bommarius, B., Lebeis, S., McNulty, S., Christensen, J., Swimm, A., Chahroudi, A., Chavan, R., Feinberg, M.B., Veach, D., Bornmann, W., Sherman, M., Kalman, D. Nat. Med. (2005) [Pubmed]
  15. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Berman, P.W., Gregory, T., Crase, D., Lasky, L.A. Science (1985) [Pubmed]
  16. Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota. Osterholm, M.T., Rambeck, J.H., White, K.E., Jacobs, J.L., Pierson, L.M., Neaton, J.D., Hedberg, C.W., MacDonald, K.L., Granoff, D.M. JAMA (1988) [Pubmed]
  17. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. Briones, J., Timmerman, J.M., Panicalli, D.L., Levy, R. J. Natl. Cancer Inst. (2003) [Pubmed]
  18. Immunity against tetanus and effect of revaccination 25-30 years after primary vaccination. Simonsen, O., Kjeldsen, K., Heron, I. Lancet (1984) [Pubmed]
  19. Thymopentin as adjuvant in non-responders or hyporesponders to hepatitis B vaccination. Záruba, K., Rastorfer, M., Grob, P.J., Joller-Jemelka, H., Bolla, K. Lancet (1983) [Pubmed]
  20. Insight into Graves' hyperthyroidism from animal models. McLachlan, S.M., Nagayama, Y., Rapoport, B. Endocr. Rev. (2005) [Pubmed]
  21. Immunoglobulin deficiency and idiotype expression in children developing Haemophilus influenzae type b disease after vaccination with conjugate vaccine. The Collaborative Study Group. Holmes, S.J., Lucas, A.H., Osterholm, M.T., Froeschle, J.E., Granoff, D.M. JAMA (1991) [Pubmed]
  22. Coupling and uncoupling of tumor immunity and autoimmunity. Bowne, W.B., Srinivasan, R., Wolchok, J.D., Hawkins, W.G., Blachere, N.E., Dyall, R., Lewis, J.J., Houghton, A.N. J. Exp. Med. (1999) [Pubmed]
  23. A targeted DNA vaccine encoding fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis. Wildbaum, G., Westermann, J., Maor, G., Karin, N. J. Clin. Invest. (2000) [Pubmed]
  24. Post-exposure prophylaxis for hepatitis B: active or passive? Iwarson, S. Lancet (1989) [Pubmed]
  25. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Langermann, S., Palaszynski, S., Sadziene, A., Stover, C.K., Koenig, S. Nature (1994) [Pubmed]
  26. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. Ashley, D.M., Faiola, B., Nair, S., Hale, L.P., Bigner, D.D., Gilboa, E. J. Exp. Med. (1997) [Pubmed]
  27. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. Huang, D.R., Wang, J., Kivisakk, P., Rollins, B.J., Ransohoff, R.M. J. Exp. Med. (2001) [Pubmed]
  28. Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. Levine, M.M., Herrington, D., Murphy, J.R., Morris, J.G., Losonsky, G., Tall, B., Lindberg, A.A., Svenson, S., Baqar, S., Edwards, M.F. J. Clin. Invest. (1987) [Pubmed]
  29. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G.A., Davis, M.M., Engleman, E.G. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  30. Fetal immunization of baboons induces a fetal-specific antibody response. Watts, A.M., Stanley, J.R., Shearer, M.H., Hefty, P.S., Kennedy, R.C. Nat. Med. (1999) [Pubmed]
  31. Vaccination against tuberculosis by DNA injection. Tascon, R.E., Colston, M.J., Ragno, S., Stavropoulos, E., Gregory, D., Lowrie, D.B. Nat. Med. (1996) [Pubmed]
  32. Impact of recommendations to suspend the birth dose of hepatitis B virus vaccine. Oram, R.J., Daum, R.S., Seal, J.B., Lauderdale, D.S. JAMA (2001) [Pubmed]
  33. Improving quality improvement using achievable benchmarks for physician feedback: a randomized controlled trial. Kiefe, C.I., Allison, J.J., Williams, O.D., Person, S.D., Weaver, M.T., Weissman, N.W. JAMA (2001) [Pubmed]
  34. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Alexopoulou, L., Thomas, V., Schnare, M., Lobet, Y., Anguita, J., Schoen, R.T., Medzhitov, R., Fikrig, E., Flavell, R.A. Nat. Med. (2002) [Pubmed]
  35. A serine/threonine kinase, Cot/Tpl2, modulates bacterial DNA-induced IL-12 production and Th cell differentiation. Sugimoto, K., Ohata, M., Miyoshi, J., Ishizaki, H., Tsuboi, N., Masuda, A., Yoshikai, Y., Takamoto, M., Sugane, K., Matsuo, S., Shimada, Y., Matsuguchi, T. J. Clin. Invest. (2004) [Pubmed]
  36. Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. Ciapponi, L., Maione, D., Scoumanne, A., Costa, P., Hansen, M.B., Svenson, M., Bendtzen, K., Alonzi, T., Paonessa, G., Cortese, R., Ciliberto, G., Savino, R. Nat. Biotechnol. (1997) [Pubmed]
  37. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Sampson, J.H., Archer, G.E., Ashley, D.M., Fuchs, H.E., Hale, L.P., Dranoff, G., Bigner, D.D. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  38. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial. MacLennan, J.M., Shackley, F., Heath, P.T., Deeks, J.J., Flamank, C., Herbert, M., Griffiths, H., Hatzmann, E., Goilav, C., Moxon, E.R. JAMA (2000) [Pubmed]
  39. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. Bloom, M.B., Perry-Lalley, D., Robbins, P.F., Li, Y., el-Gamil, M., Rosenberg, S.A., Yang, J.C. J. Exp. Med. (1997) [Pubmed]
  40. Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. Shahin, R.D., Brennan, M.J., Li, Z.M., Meade, B.D., Manclark, C.R. J. Exp. Med. (1990) [Pubmed]
  41. DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response. Mimran, A., Mor, F., Carmi, P., Quintana, F.J., Rotter, V., Cohen, I.R. J. Clin. Invest. (2004) [Pubmed]
  42. Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Meuer, S.C., Dumann, H., Meyer zum Büschenfelde, K.H., Köhler, H. Lancet (1989) [Pubmed]
WikiGenes - Universities